Support and Resistance Levels
Past performance
About RPG Life Sciences Ltd RPG Life Sciences Ltd, a part of the RPG Group, is a prominent player in the pharmaceutical industry, focusing on manufacturing and marketing Formulations and Active Pharmaceutical Ingredients (APIs). Established in 1968 as a joint venture with GD Searle, USA, the company now operates independently following GD Searle's exit in 1993. With research and development facilities meeting international standards, RPG Life Sciences has expanded its portfolio across various therapeutic segments, including oncology, immunosuppressants, cardiology, and nephrology.
The company has a history of strategic acquisitions and expansions, including the acquisition of Brabourne Enterprises Ltd's pharmaceutical business in 2007 and the sale of its Biotech unit to Intas Pharmaceuticals in 2016-17. RPG Life Sciences has introduced a range of new products, strengthened its presence in emerging markets like Africa, and remains a leader in Mauritius and Egypt. The company's expansion strategy includes launching new products, setting up dedicated divisions, and filing DMFs in regulated markets.